Spinraza-Zolgensma Combination Well-tolerated in Children with SMA Type 1, Study Shows
Combining Spinraza (nusinersen) with the gene therapy Zolgensma (onasemnogene abeparvovec-xioi) is generally well-tolerated and sustains motor improvements in children with spinal muscular atrophy (SMA) type 1, according to a case series study. The data, which...
Late-Breaking SMA Treatment Insights You May Have Missed in February
February wrapped up with a surge of data on SMA, including novel investigations into how combinatorial therapies may provide new advantages to those with the disease. More information on how nusinersen impacts patients has also become available, as have new findings...
SMA HCP News December Round-up: Spinal Cord Hypoxia, Scoliosis Surgery & More
Regulators continue to review SMA drugs and consider policies related to newborn screening while new data emerge related to the mechanisms underlying the disease, as well as those concerning management and treatment. Here is a roundup of some of the latest news and...
Spinal Muscular Atrophy: Late October 2019 Roundup
Data on SMA continue to roll out. This month has shown a growing focus and understanding on issues related to nusinersen as well as newborn screening for SMA across the globe. In addition, more preclinical and translation results have been published. Below is the...
Spinal Muscular Atrophy: Mid-October 2019 Roundup
The beginning of fall has seen a steady stream of new data elucidating SMA mechanisms, as well as options for managing and treating the disease. There have also been reports of evolving efforts to optimize both SMA research and clinical care, such as through a new SMA...HCP — SMA News Today
BioNews Services, LLC
3 W Garden St
Suite 354
Pensacola, FL 32502
Email: [email protected]
Phone: 1-800-936-1363